Skip to main content

Advertisement

SpringerLink
Log in

The role of imatinib plasma level testing in gastrointestinal stromal tumor

  • Supplement (SPECIAL ISSUE)
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The management of patients with gastrointestinal stromal tumor (GIST) has markedly advanced over the past 10 years. Imatinib has exceptional activity in controlling gastrointestinal stromal tumor (GIST) due to inhibition of the constitutively active conformation of KIT and PDGFRA which is found in the majority of patients with GIST. Although some patients may experience prolonged disease control while on imatinib, most patients will develop imatinib resistance within 2–3 years on therapy. A recent retrospective analysis demonstrated a relationship between imatinib plasma levels and progression-free survival in patients with advanced GIST. Plasma imatinib levels in this study were unrelated to the daily administered dose of imatinib. A prospective trial is underway in order to evaluate whether modification of imatinib dose to achieve a target imatinib plasma level will impact patient outcome when compared to standard imatinib dosing in GIST (http://www.clinicaltrials.gov, NCT01031628).  This review will explore the current available data on the relationship between imatinib plasma levels, response to treatment, and other prognositic factors as well as discuss the implications of this data for possible future therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Blanke C, Rankin C, Demetri G et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. JCO 26:626–632

    Article  CAS  Google Scholar 

  2. Blanke C, Demetri G, Von Mehren M et al (2008) Long-term results from a randomized phase ii trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. JCO 25:620–625

    Google Scholar 

  3. Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33(5):459–465

    Article  PubMed  Google Scholar 

  4. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580

    Article  CAS  PubMed  Google Scholar 

  5. Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152(5):1259–1269

    CAS  PubMed  Google Scholar 

  6. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052–1056

    Article  CAS  PubMed  Google Scholar 

  7. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

    Article  CAS  PubMed  Google Scholar 

  8. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23(2):70–83

    Article  PubMed  Google Scholar 

  9. Martin-Broto J, Gutierrez A, Garcia-Del-Muro X et al (2010) Prognostic time dependence of deletions affecting condons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish group for sarcoma research (GEIS) study. Ann Oncol 21:1552–1557

    Article  CAS  PubMed  Google Scholar 

  10. Keun Park C, Lee EJ, Kim M et al (2008) Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 247(6):1011–1018

    Article  PubMed  Google Scholar 

  11. Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342–4349

    Article  CAS  PubMed  Google Scholar 

  12. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22(18):3813–3825

    Article  CAS  PubMed  Google Scholar 

  13. Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) EORTC soft tissue and bone sarcoma group; The Italian sarcoma group; Australasian gastrointestinal trials group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42(8):1093–1103

    Article  CAS  PubMed  Google Scholar 

  14. Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708–710

    Article  CAS  PubMed  Google Scholar 

  15. Heinrich M, Owzar K, Corless C et al (2008) Correlation of kinase genotype and clinical outcome in the north american intergroup phase iii trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: calgb 150105 study by cancer and leukemia group B and Southwest oncology group. JCO 26:5360–5367

    Article  CAS  Google Scholar 

  16. Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42(8):1093–1103

    Article  CAS  PubMed  Google Scholar 

  17. Gastrointestinal Tumor Meta-analysis Group (metaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: an analysis of 1,640 patients. JCO 28(7):1247–1253

    Article  Google Scholar 

  18. Zalcberg JR, Verweij J, Casali PG et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eu J Cancer 41:1751–1757

    Article  CAS  Google Scholar 

  19. Liegl B, Kepten I, Le C et al (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216(1):64–74

    Article  CAS  PubMed  Google Scholar 

  20. Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of imatinib therapy for newly diagnosed myeloid leukemia in chronic-phase shows sustained responses and high overall survival. New Engl J Med 355:2408–2417

    Article  CAS  PubMed  Google Scholar 

  21. Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic, molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496–3499

    Article  CAS  PubMed  Google Scholar 

  22. Larson R, Druker B, Guilhot F et al (2008) Imatinib pharmacokinetics, its correlation with response, safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022–4028

    Article  CAS  PubMed  Google Scholar 

  23. Delbaldo C, Chatelut E, Re M et al (2006) Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12:6073–6078

    Article  CAS  PubMed  Google Scholar 

  24. Demetri GD, Wang Y, Wehrle E et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141–3147

    Article  CAS  PubMed  Google Scholar 

  25. Widmer N, Decosterd L, Leyvraz S et al (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98:1633–1640

    Article  CAS  PubMed  Google Scholar 

  26. Judson I, Ma P, Peng B et al (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumor: a retrospective population pharmacokinetic study over time. EORTC soft tissue and bone sarcoma group. Cancer Chemother Pharmacol 55:379–386

    Article  CAS  PubMed  Google Scholar 

  27. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–894

    Article  CAS  PubMed  Google Scholar 

  28. Petain A, Kattygnarath D, Azard J et al (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14(21):7102–7109

    Article  CAS  PubMed  Google Scholar 

  29. Gardner ER, Burger H, van Schiek RH et al (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharm Ther 80(20):192–201

    CAS  Google Scholar 

  30. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myelogenous leukemia. N Eng J Med 344:1031–1037

    Article  CAS  Google Scholar 

  31. Yoo C, Ryu MH, Kang BW et al (2010) Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28:1554–1559

    Article  CAS  PubMed  Google Scholar 

  32. Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-Italian sarcoma group-Australasian gastrointestinal trials group study. J Clin Oncol 23(24):5795–5804

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Logistical support during submission of this article was provided by Springer Healthcare LLC. This support was funded by Novartis.

Conflict of interest

Dr. Suzanne George: Novartis and Pfizer Advisory Boards; Dr. Jonathan C. Trent: I have clinical trial support, honoraria from Novartis Pharmaceuticals. I have laboratory support from Merck Pharmaceuticals.

Author information

Authors and Affiliations

  1. Harvard Medical School, Clinical Director Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Suzanne George

  2. Department of Sarcoma Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA

    Jonathan C. Trent

Authors
  1. Suzanne George
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan C. Trent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suzanne George.

Rights and permissions

Reprints and permissions

About this article

Cite this article

George, S., Trent, J.C. The role of imatinib plasma level testing in gastrointestinal stromal tumor . Cancer Chemother Pharmacol 67 (Suppl 1), 45–50 (2011). https://doi.org/10.1007/s00280-010-1527-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1527-2

Keywords

Search

Navigation